Similar articles

• [Chronic myeloid leukemia and imatinib mesylate therapy].

  Chrobák L. Chrobák L. Vnitr Lek. 2004 Jan;50(1):10-2. Vnitr Lek. 2004. PMID: 15015223 Czech. No abstract available.
• Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.

  Richardson MW, Grewal SS. Richardson MW, et al. Pediatr Blood Cancer. 2008 Jan;50(1):186. doi: 10.1002/pbc.21217. Pediatr Blood Cancer. 2008. PMID: 17455313 No abstract available.
• [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].

  Nausová J, Priwitzerová M, Jarosová M, Indrák K, Faber E, Divoký V. Nausová J, et al. Cas Lek Cesk. 2006;145(5):377-82. Cas Lek Cesk. 2006. PMID: 16755775 Czech.
• Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.

  Marcucci G, Perrotti D, Caligiuri MA. Marcucci G, et al. Clin Cancer Res. 2003 Apr;9(4):1248-52. Clin Cancer Res. 2003. PMID: 12684391 Review. No abstract available.
• Important therapeutic targets in chronic myelogenous leukemia.

  Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J. Kantarjian HM, et al. Clin Cancer Res. 2007 Feb 15;13(4):1089-97. doi: 10.1158/1078-0432.CCR-06-2147. Clin Cancer Res. 2007. PMID: 17317816 Review.